sector medic suppli devic
 impella could
 rais pt
messag mark second straight quarter acceler growth
sale yoy strength shock rp rather rehash
fundament cover past note thought address anoth
question stock continu work recent run ytd
vs valuat ntm sale hit level rare seen
med-tech simpli put despit success date think may
get start pt goe reiter buy rate
still best growth stori med-tech first made claim month ago
thesi base saw uniqu combin near-term growth
address market opportun lack competit profit balanc
sheet strength forward today mani factor identifi time
potenti catalyst continu impella adopt come pass includ improv
reimburs rp pma approv expans japan one
radar time believ may actual signific bunch
push standard cardiogen shock treatment nation csi program
see effort still earli inning today may alreadi
posit impact impella volum
check plan year septemb laid
vision impella adopt paint scenario sale could reach
end period ambiti goal compani time
revenu base like fall short mark base
current estim compani still deliv impress top-lin momentum post
revenu compound-annual-growth-rate meanwhil actual ahead schedul
profit guidanc impli ebit margin could approach year
earlier origin expect common question gotten investor
recent whether long-term growth potenti busi possibl
justifi valuat stock
impella valu base dcf analysi believ compani
uniqu fundament make difficult comp peer ev/sal basi
natur process forc us think busi could year
case thought exercis lead interest conclus start
compani total address market follow recent label expans includ
high-risk pci patient preserv eject fraction emerg patient
acut cardiomyopathi peg market opportun
consid addit opportun impella stemi patient
get visibl result dtu feasibl trial present
possibl soon tct septemb meanwhil german japanes market
alon add anoth intern despit impress success date
math suggest thu far penetr avail opportun
look ahead estim global impella sale could climb
assum penetr high-risk pci emerg patient popul
increas respect greater adopt shock driven better
standard treatment protocol forecast includ revenu stemi
impella use bridge-to-recoveri tool patient advanc heart failur meanwhil
estim ou sale contribut total driven continu adopt
germani japan eventu expans geographi well note
japan recent join germani downgrad iabp class recommend
shock believ clear way mechan circulatori support eventu
becom standard care market continu page
page analyst certif import disclosur
meanwhil see plenti headroom margin well model call
abiom oper profit peak assum gross margin
declin today driven modest price eros time
meanwhil forecast sg declin sale spend
drop revenu
what compani sale ebit margin worth
fortun there comp achiev combin top-lin growth
profit would rare feat done fact figur
show forecast could look like match close
today despit recent run would need
see market cap expand anoth come decad match
market current valu intuit suggest us stock still signific
figur impella revenu
factset guggenheim secur llc estim
report guggenheim secur llc
cours get wont easi believ intuit success past
decad driven number factor includ larg
differenti product offer capabl deliv superior clinic result compar
prior standard care lack direct competit willing obsolet
product time constant innov strong execut abiom
check box well view that guarante
enjoy level success see thought exercis instruct frame
compani upsid potenti
estim move higher reiter buy model call
report adjust ep total revenu
compar prior forecast respect rais
dcf-deriv price target base revis estim lower
discount rate vs previous believ accur reflect
compani cost capit signific upsid potenti target current
level reiter buy rate
page analyst certif import disclosur
leader mechan circulatori support dedic enabl safer
treatment high-risk patient cardiovascular diseas recov injur heart
muscl estim patient receiv one compani famili impella
heart pump year yet believ scratch surfac impella
long-term potenti estim market opportun includ
stemi see long runway growth level compani match
impella smallest heart pump world design provid temporari
hemodynam support patient undergo high-risk procedur whose cardiac
function compromis sinc impella first receiv approv
impella famili pump use support ten thousand peopl
 alon revenu grow compound-annual-growth-rate period go
forward expect ramp penetr protect pci opportun
penetr cardiogen shock opportun penetr indic
drive continu strong growth compani still earli inning
capit intern opportun impella well recent guidelin
chang germani entri japanes market provid ampl momentum
go forward model call grow total revenu compound-annual-growth-rate
combin strong margin clean balanc sheet limit competit
view arguabl best growth stori med-tech
share trade ntm revenu estim signific premium
multipl high-growth peer smid-cap med-tech group believ
abiom uniqu combin top line growth potenti compound-annual-growth-rate
profit gm om make compani difficult valu base
tradit metric result employ discount cash flow methodolog deriv
fair valu estim assum wacc previous
termin growth rate calcul forward npv per share previous
previous use discount rate compani true cost
capit take account uncertainti forward project howev base
chang japanes approv on-going strength base busi longer
believ risk adjust necessari new target equat multipl
forward ntm sale estim signific potenti upsid target
current level assign buy rate
downsid risk rate price target includ potenti impella adopt
fall short street forecast pipelin setback clinic failur weaken
abiom long-term outlook faster-than-expect progress potenti impella
competitor premium valuat leav littl margin error view
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
million usd
servic
revenu geographi
 unit
 unit indic
compani report guggenheim secur llc estim
page analyst certif import disclosur
